During the last session, Exact Sciences Corporation (NASDAQ:EXAS)’s traded shares were 2.01 million, with the beta value of the company hitting 1.36. At the end of the trading day, the stock’s price was $39.49, reflecting an intraday gain of 3.81% or $1.45. The 52-week high for the EXAS share is $133.99, that puts it down -239.3 from that peak though still a striking 10.51% gain since the share price plummeted to a 52-week low of $35.34. The company’s market capitalization is $6.68B, and the average intraday trading volume over the past 10 days was 2.52 million shares, and the average trade volume was 2.14 million shares over the past three months.
Exact Sciences Corporation (EXAS) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.60. EXAS has a Sell rating from 0 analyst(s) out of 20 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 3 suggest Overweight, and 14 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$1.06.
Exact Sciences Corporation (NASDAQ:EXAS) trade information
Exact Sciences Corporation (EXAS) registered a 3.81% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.81% in intraday trading to $39.49 this Wednesday, 06/22/22, hitting a weekly high. The stock’s 5-day price performance is 6.33%, and it has moved by -25.73% in 30 days. Based on these gigs, the overall price performance for the year is -69.13%. The short interest in Exact Sciences Corporation (NASDAQ:EXAS) is 13.59 million shares and it means that shorts have 7.01 day(s) to cover.
The consensus price target of analysts on Wall Street is $96.53, which implies an increase of 59.09% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $50.00 and $160.00 respectively. As a result, EXAS is trading at a discount of -305.17% off the target high and -26.61% off the low.
Exact Sciences Corporation (EXAS) estimates and forecasts
Statistics show that Exact Sciences Corporation has underperformed its competitors in share price, compared to the industry in which it operates. Exact Sciences Corporation (EXAS) shares have gone down -50.18% during the last six months, with a year-to-date growth rate less than the industry average at -22.13% against 0.60. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -2.90% this quarter and then drop -10.30% in the quarter after that. In the rating firms’ projections, revenue will increase 14.50% compared to the previous financial year.
Revenue for the current quarter is expected to be $498.27 million as predicted by 14 analyst(s). Meanwhile, a consensus of 15 analyst(s) estimates revenue growth to $511.02 million by the end of Sep 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $434.82 million and $456.38 million respectively. In this case, analysts expect current quarter sales to grow by 14.60% and then jump by 12.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -16.30%. While earnings are projected to return 36.20% in 2022.
Exact Sciences Corporation is due to release its next quarterly earnings between May 02 and May 06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Exact Sciences Corporation (NASDAQ:EXAS)’s Major holders
Exact Sciences Corporation insiders own 0.88% of total outstanding shares while institutional holders control 93.54%, with the float percentage being 94.38%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 815 institutions own stock in it. As of Dec 30, 2021, the company held over 15.43 million shares (or 8.77% of all shares), a total value of $1.2 billion in shares.
The next largest institutional holding, with 14.32 million shares, is of ARK Investment Management, LLC’s that is approximately 8.14% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $1.0 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Exact Sciences Corporation (EXAS) shares are ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund. Data provided on Feb 27, 2022 indicates that ARK ETF Tr-ARK Innovation ETF owns about 8.31 million shares. This amounts to just over 4.73 percent of the company’s overall shares, with a $649.02 million market value. The same data shows that the other fund manager holds slightly less at 4.9 million, or about 2.79% of the stock, which is worth about $381.54 million.